Targovax announces that the TG01 study in multiple myeloma at Oslo University Hospital has received regulatory approvals to proceed
· The Norwegian Medicines Agency (NOMA) and the Regional Ethics Committee (REK) have today approved the clinical trial application for TG01 in multiple myeloma · The Norwegian Medicines Agency (NOMA) and the Regional Ethics Committee (REK) have today approved the clinical trial application for TG01 in multiple myeloma · It is expected that the study will open, and the first patient will be enrolled at Oslo University Hospital (OUS) in early 2023 Oslo, Norway, 22 December 2022 – Targovax ASA (OSE: TRVX), a clinical-stage immuno-oncology company developing immune activators to